{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/constipation/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f4d419f5-dfbc-54c7-b9e9-89991528af48","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 8e2cbff6-a131-4eaf-812d-eebf0c3ce0f8 --><h2>Changes</h2><!-- end field 8e2cbff6-a131-4eaf-812d-eebf0c3ce0f8 -->","summary":null,"htmlStringContent":"<!-- begin item 410cd5c5-0208-4b07-98ee-391d63c30b31 --><!-- begin field 716f55a7-726a-4de4-a6f5-a30724c4432b --><p><strong>November 2020</strong> — minor update. Ischaemic colitis (macrogol) has been added as a caution for prescribing laxatives in line with revised manufacturer's SPC.</p><p><strong>September 2020</strong> — minor update. A broken hyperlink was updated. </p><p><strong>May 2020 </strong>— minor update. A recommendation to consider prescribing lubiprostone for people with chronic constipation has been removed as the product has been discontinued. </p><p><strong>June 2019</strong> — minor update. Advice that Movicol is considered high in sodium has been added to the prescribing information [<a class=\"bibliography-reference internal-reference\" href=\"/topics/constipation/references/\">ABPI, 2019</a>].</p><p><strong>June 2017 </strong>— reviewed. A literature search was conducted in June 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The lower age limit of the topic has been changed to 18 years. The recommendations on assessment have been expanded, and the management options in primary care have been amended in line with current evidence. The scenario on pregnancy and breastfeeding has been incorporated into the scenario on the management of adults with constipation. The Prescribing information section has been updated.</p><!-- end field 716f55a7-726a-4de4-a6f5-a30724c4432b --><!-- end item 410cd5c5-0208-4b07-98ee-391d63c30b31 -->","topic":{"id":"88cc63e8-cda0-5ec1-9109-ae5f4bfa11e3","topicId":"f48a0909-280f-4498-b297-07190c08ba54","topicName":"Constipation","slug":"constipation","lastRevised":"Last revised in November 2020","chapters":[{"id":"652b9d37-6de5-5916-9013-64708458d208","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"602fea2a-9883-51cc-9131-86d54e1113e9","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"eae1c7f5-9d3d-5ff3-a31a-7ff5aa5d2b7f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f4d419f5-dfbc-54c7-b9e9-89991528af48","slug":"changes","fullItemName":"Changes"},{"id":"f186f2b1-9c45-56b4-a1b7-8f5a64a55f86","slug":"update","fullItemName":"Update"}]},{"id":"c2b304c9-3b12-5ee7-81ca-b9ea44de8ad2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1f8da0ad-6b3f-5b74-b978-502804c2464e","slug":"goals","fullItemName":"Goals"},{"id":"094c26e0-e5de-57ad-8f83-0874e217917b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"183d066c-25c1-5ad6-91ad-2f1ddaf48844","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5728a841-2eb8-5a93-928f-78962810589e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e8aec3c8-dcd5-529d-b1e6-4e64bf325751","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b41e9ad7-b6f1-5370-9ab2-824d00965a97","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"644e0758-3407-5c39-b900-549da92e4b67","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"793f8115-0d16-56ae-9aa8-36081e7b05c1","slug":"definition","fullItemName":"Definition"},{"id":"845578b1-5eae-5964-be4f-428a0e1b7917","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e98889d3-a808-5164-9182-e7e91ec41a5a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ffec4b77-cf61-5457-a0f5-ce1e0f586efd","slug":"secondary-causes","fullItemName":"Secondary causes"},{"id":"2ee90a5b-045c-53d9-b959-152df5ad7f47","slug":"complications","fullItemName":"Complications"},{"id":"43476423-3756-5b1e-9830-62652bc204fa","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"20a02d1d-6083-5d12-9a37-2341374ee49e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0fb11d37-0b97-560c-9521-31e3e92b8521","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"59b36c20-e883-5b08-b36a-485a711db9da","slug":"assessment","fullItemName":"Assessment"}]},{"id":"af868597-08db-5b93-8dad-450f291d1a9e","fullItemName":"Management","slug":"management","subChapters":[{"id":"e7e6858e-631c-50fa-b152-6f3e159172f2","slug":"adults","fullItemName":"Scenario: Adults"}]},{"id":"01aa9990-5973-577b-83b3-984de168d2ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c8b1ca22-3ea7-54d7-a60e-085a99978b86","slug":"choice-of-laxatives","fullItemName":"Choice of laxatives"},{"id":"c6802d37-3b6e-56ae-b981-bf5a1fa73dfa","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions"},{"id":"a9857941-fb3d-5c45-a169-a10e8b051874","slug":"factors-affecting-choice-of-laxative","fullItemName":"Factors affecting choice of laxative"},{"id":"07a053e7-81a8-5cdd-a703-648169d42d57","slug":"adverse-effects-of-laxatives","fullItemName":"Adverse effects of laxatives"}]},{"id":"5c976ceb-9cd2-5109-96f3-46103c161ded","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"b23b11d4-8313-5155-aa23-31f0a397d85d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fdead64f-db75-5e71-bab5-4a4fb444a78e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e902c099-4ac5-500b-90a6-fee9ea7e517f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"48884da3-b344-59b5-9e59-a14de8e35504","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9e2d6345-692d-564f-8200-2d89db123fc2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cca0beff-c1e5-54df-88e2-1b00d48dfeb0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"632aae60-b457-578c-9502-2e434b5ca3e0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eae1c7f5-9d3d-5ff3-a31a-7ff5aa5d2b7f","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ed03dea5-40fc-5362-83fb-b28ed89e3290","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e9168961-dae1-4613-a1b9-3e110454e707 --><h3>Previous changes</h3><!-- end field e9168961-dae1-4613-a1b9-3e110454e707 -->","summary":null,"htmlStringContent":"<!-- begin item 70ed26f1-c402-4637-9609-f7c70b6b9116 --><!-- begin field c3fadd26-7c3d-4185-a815-462556e02e2f --><p><strong>December 2016</strong> — minor update. The prescribing information for prucalopride has been updated in line with the manufacturer's Summary of Product Characteristics (SPC), as it is now licensed for use in men. </p><p><strong>October 2015 </strong>—<strong> </strong>minor update. Minor typographical error corrected.</p><p><strong>February 2015 </strong>—<strong> </strong>minor update. Update to the text on the use of docusate in pregnancy following feedback from a CKS user. The recommendation to use lower doses of docusate during pregnancy has been removed, as it was based on an outdated text. The normal licensed dose is recommended as there is no evidence of an increased risk of fetal malformations with the use of docusate during pregnancy, in line with the UK Teratology Information Service (UKTIS) monograph <em>Treatment of constipation in pregnancy</em> (2013).</p><p><strong>September 2014 </strong>— minor update. Addition of lubiprostone as a treatment option for chronic idiopathic constipation in adults as recommended by the National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance <em>Lubiprostone for treating chronic idiopathic constipation</em> (2014). In addition, removal of the detailed evidence section on prucalopride, and a summary of the evidence on the use of prucalopride has been inserted into the relevant basis of recommendation section, in line with the NICE technology appraisal guidance <em>Prucalopride for the treatment of chronic constipation in women</em> (2010).</p><p><strong>April 2014 </strong>— minor update. Text changes to prescribing information for Fleet Ready-to-Use phosphate enema to reflect the addition of renal impairment and dehydration to the contraindications section of the Summary of Product Characteristics (2014).</p><p><strong>December 2013 </strong>— minor update. The link to the UK Medicines Information (UKMI) drugs in lactation website has been removed as this no longer exists.</p><p><strong>September 2013 </strong>— minor update. The basis for recommendation section for managing constipation in pregnancy in the Scenario on Pregnancy or breastfeeding has been amended to reflect the fact that Movicol<sup>® </sup>preparations are now licensed for use in pregnancy. However, CKS does not recommend macrogols because there are limited data on their use in pregnancy, and there are other laxatives available for which there is more anecdotal experience for use in pregnancy.</p><p><strong>January 2013 </strong>— reviewed. A literature search was conducted in November 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Minor changes to clinical recommendations have been made, and information about prucalopride has been added.</p><p><strong>November 2012 </strong>—<strong> </strong>minor update. The links to the electronic Medicines Compendium (eMC) website have been updated (available at www.medicines.org.uk).</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>September 2010 </strong>— updated. The management of constipation in children has been removed from this topic, and is now covered in the separate CKS topic on Constipation in children. Issued in September 2010.</p><p><strong>August 2009 </strong>— minor update. Advice from the National Institute for Health and Care Excellence (NICE) guideline on when to suspect child maltreatment has been added to this topic. Issued in August 2009.</p><p><strong>October 2007 to January 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The section on <em>How do I manage constipation in the terminally ill? </em>has been removed because this is covered in the CKS topic on Palliative care - constipation. There are no major changes to the recommendations for treatments. However, the advice on treatment strategies has been clarified, with more detail on the advantages and disadvantages of different laxatives, and more detail on foods and diets that may be useful in managing constipation.</p><p><strong>June 2007 </strong>— minor update. Text now indicates that use of phosphate enemas for hard impacted stools is an off-licence use. Issued June 2007.</p><p><strong>May 2007 </strong>— minor update to text and to senna prescriptions. Issued May 2007.</p><p><strong>March 2007 </strong>— minor update to text and to macrogols and electrolytes prescriptions. Issued in March 2007.</p><p><strong>January 2006 </strong>— minor technical update. Issued in February 2006.</p><p><strong>June 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>April 2002 </strong>— reviewed. Validated in June 2002 and issued in July 2002.</p><p><strong>July 2000 </strong>— updated to incorporate the Committee on Safety of Medicines (CSM) advice to restrict the indications for the use of dantron for constipation in terminally ill people.</p><p><strong>June 1999 </strong>— written and validated.</p><!-- end field c3fadd26-7c3d-4185-a815-462556e02e2f --><!-- end item 70ed26f1-c402-4637-9609-f7c70b6b9116 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}